A study mapped pre-treatment gene signatures combining immune activity markers with tumor-intrinsic signals linked to SLC7A5 and SOX2 to PD-1 blockade response and resistance in advanced cutaneous squamous cell carcinoma. The work suggests that both microenvironmental and tumor-intrinsic programs may predict who benefits and who may not. For immunotherapy developers, this type of dual-context signature can guide patient stratification, trial enrichment, and companion diagnostic development. It also highlights why single-dimension biomarkers often underperform in heterogeneous cancers. Details of validation cohorts weren’t provided in the brief, so the next incremental value will come from prospective testing and reproducibility across centers.